GlobalData's analysis alert "The Rheumatoid Arthritis Community is Swelling with Anticipation as its Research Pipeline Begins to Burst, analyzes the current pipeline for rheumatoid arthritis drug therapeutics. In addition to the anticipated upcoming approval of Pfizers tofacitinib, the pipeline has other entities waiting in the wings. Tofacitinib conquers the troublesome formulation issue as it is administered in oral doses, but other compounds are in development in oral form as well. Tofacitinib also tackles the JAK pathway which current RA therapies do not target, and there are other kinase inhibitors in the development pipeline. Also, there is the possibility of a DNA vaccine which will minimize early symptoms of RA. Finally, we look at a new potential pathway to target in order to inhibit inflammation and joint destruction for people suffering from RA.
- Details of select upcoming RA therapies with clinical trial results.
- Discussion of a possible new pathway which may be involved with the promotion of RA.
Reasons to buy
- Important details of the select RA therapies are discussed along with ACR response results from clinical trials.
- Stay informed about the RA pipeline, which has an abundance of activity, and some unmet needs will be answered in the near future.